Emerging Biopharma: Striving for Optimal Commercial Positioning
March 20th 2024In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the important and often missing element in strategic planning for clinical-stage companies—and ways to close that focus gap.
PAP 2024: Michael Galarraga Discusses "The State of Patient Access and Affordability”
March 20th 2024In an interview with Pharma Commerce Associate Editor Don Tracy, Michael Galarraga, LPC, ATR-BC, Pennsylvania State Representative, OutCare Health offers his thoughts on the breakout session and his experience in mental health counseling.
A Tougher Road for Startups in Selling Their Value Story
March 19th 2024In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, talks about the challenging environment today for emerging biopharma companies in demonstrating the value of their promising early-stage drug candidates to potential investors or buyers.
Reading the Tea Leaves on Recent Surge in Pharma Dealmaking
March 18th 2024In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead.
Incyte’s Phase II Study for Opzelura Returns Promising Results in Adult Patients
March 11th 2024The company’s twice-daily, branded ruxolitinib cream 1.5% presents a significant reduction in abscess and inflammatory nodule (AN) count for the treatment of Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa.